MX2022007679A - Composiciones purificadas de enterovirus y metodos de purificacion por cromatografia de afinidad con glutation. - Google Patents

Composiciones purificadas de enterovirus y metodos de purificacion por cromatografia de afinidad con glutation.

Info

Publication number
MX2022007679A
MX2022007679A MX2022007679A MX2022007679A MX2022007679A MX 2022007679 A MX2022007679 A MX 2022007679A MX 2022007679 A MX2022007679 A MX 2022007679A MX 2022007679 A MX2022007679 A MX 2022007679A MX 2022007679 A MX2022007679 A MX 2022007679A
Authority
MX
Mexico
Prior art keywords
enteroviruses
purification
affinity chromatography
methods
glutathione affinity
Prior art date
Application number
MX2022007679A
Other languages
English (en)
Inventor
Erik M Curtis
Spyridon Konstantinidis
Murphy Poplyk
Andrew Ryan Swartz
Marc D Wenger
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of MX2022007679A publication Critical patent/MX2022007679A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32351—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a composiciones purificadas de enterovirus, composiciones farmacéuticas de los mismos y a un proceso de cromatografía de afinidad con glutatión para la purificación de los enterovirus.
MX2022007679A 2019-12-20 2020-12-17 Composiciones purificadas de enterovirus y metodos de purificacion por cromatografia de afinidad con glutation. MX2022007679A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962951078P 2019-12-20 2019-12-20
PCT/US2020/065572 WO2021127155A1 (en) 2019-12-20 2020-12-17 Purified compositions of enteroviruses and methods of purification with glutathione affinity chromatography

Publications (1)

Publication Number Publication Date
MX2022007679A true MX2022007679A (es) 2022-07-19

Family

ID=74191844

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007679A MX2022007679A (es) 2019-12-20 2020-12-17 Composiciones purificadas de enterovirus y metodos de purificacion por cromatografia de afinidad con glutation.

Country Status (12)

Country Link
US (1) US20210187049A1 (es)
EP (1) EP4077644A1 (es)
JP (1) JP2023510133A (es)
KR (1) KR20220122678A (es)
CN (1) CN114829589A (es)
AR (1) AR120794A1 (es)
AU (1) AU2020405026A1 (es)
BR (1) BR112022012221A2 (es)
CA (1) CA3162365A1 (es)
MX (1) MX2022007679A (es)
TW (1) TW202138556A (es)
WO (1) WO2021127155A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022132988A1 (en) * 2020-12-17 2022-06-23 Merck Sharp & Dohme Corp. Enterovirus purification with cation exchange chromatography
WO2023139224A1 (en) * 2022-01-20 2023-07-27 Sartorius Xell GmbH METHOD FOR THE DETECTION AND QUANTIFICATION OF ADENO-ASSOCIATED VIRUSES (AAVs) USING AN AFFINITY MATRIX

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107073099B (zh) 2014-02-27 2022-09-27 默沙东公司 用于治疗癌症的联合方法
CA2995385A1 (en) * 2015-08-20 2017-02-23 Genentech, Inc. Purification of fkpa and uses thereof for producing recombinant polypeptides
CN107849122B (zh) * 2015-08-21 2022-01-25 豪夫迈·罗氏有限公司 用低电导率洗涤缓冲液进行亲和层析纯化
EP3560945A1 (en) * 2018-04-27 2019-10-30 F. Hoffmann-La Roche AG Methods for purification of polypeptides using polysorbates

Also Published As

Publication number Publication date
EP4077644A1 (en) 2022-10-26
CA3162365A1 (en) 2021-06-24
US20210187049A1 (en) 2021-06-24
CN114829589A (zh) 2022-07-29
JP2023510133A (ja) 2023-03-13
WO2021127155A1 (en) 2021-06-24
AR120794A1 (es) 2022-03-16
BR112022012221A2 (pt) 2022-09-13
KR20220122678A (ko) 2022-09-02
TW202138556A (zh) 2021-10-16
AU2020405026A1 (en) 2022-06-16

Similar Documents

Publication Publication Date Title
PH12018500034A1 (en) Bicyclic lactams and methods of use thereof
NZ734714A (en) Methods of purifying cannabinoids, compositions and kits thereof
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
PH12017502024A1 (en) (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
WO2018178334A3 (fr) Purification des phycobiliproteines
MX2018015654A (es) Cromatografía de interacción hidrofóbica para la purificación de oligonucleótidos.
MX2022007679A (es) Composiciones purificadas de enterovirus y metodos de purificacion por cromatografia de afinidad con glutation.
MX2021004902A (es) Metodo para utilizar gas industrial que contiene co2 para la produccion de una composicion de gas enriquecida con metano.
NZ743910A (en) Purification of iduronate-2-sulfatase
MX2020005653A (es) Compuestos para la separacion de elementos de tierras raras y metales s, p, d, metodo de separacion y uso de estos.
WO2015021423A3 (en) Purification of chimeric fviii molecules
MY184725A (en) Process for the purification of biomass hydrolysate
EA201691834A1 (ru) Новый способ очистки гонадотропина
EA201990593A1 (ru) Непрерывный способ для снижения гетерогенности терапевтического белка
AU2013212209A8 (en) (1R,4R) 7-oxo-2-azabicyclo[2.2.2]oct-5-ene and derivatives thereof
WO2019224548A3 (en) Methods for the production of methacrylates
CR20220228A (es) Anticuerpos trem2 y usos de estos
MX2019002017A (es) Derivados de sofosbuvir para el tratamiento de la hepatitis c.
WO2020012408A3 (en) A process for purification of protected polycyclic carbamoylpyridone derivatives
MX2020002914A (es) Composiciones, usos y procedimientos para el tratamiento de la infertilidad y la subfertilidad.
MX2019005785A (es) Proceso para la purificacion de 1-(4-clorofenil)pirazol-3-ol.
PH12021551008A1 (en) Purification method for vaccine virus using affinity chromatography
ZA202203248B (en) Bicyclic compound and use thereof
MX2020010343A (es) Proceso para la purificacion de biocomposiciones complejas.
IN2014CH01392A (es)